Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

BACKGROUND: The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute to the inflammatory processes. Lenzilumab, a GM-CSF neut...

Descripción completa

Detalles Bibliográficos
Autores principales: Temesgen, Zelalem, Burger, Charles D, Baker, Jason, Polk, Christopher, Libertin, Claudia R, Kelley, Colleen F, Marconi, Vincent C, Orenstein, Robert, Catterson, Victoria M, Aronstein, William S, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635458/
https://www.ncbi.nlm.nih.gov/pubmed/34863332
http://dx.doi.org/10.1016/S2213-2600(21)00494-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635458/
https://www.ncbi.nlm.nih.gov/pubmed/34863332
http://dx.doi.org/10.1016/S2213-2600(21)00494-X

Ejemplares similares